Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Specialty — Gross Profit

Other segment segments

Affordable Medicines
$207.23M+14.6%
AvKARE
$26.25M-21.0%

Similar metrics at other companies

Balchem logo
BCPCSpecialty Products — Gross Profit
$20.46M+18.4%
Ascent Industries Co. logo
ACNTSpecialty Chemicals — Gross Profit
$2.81M-25.0%
Church & Dwight logo
CHDSpecialty Products Division — Gross Profit
$29.1M+0.3%
Scansource logo
SCSCSpecialty Technology Solutions — Gross Profit
$81.42M+10.0%
RCM Technologies logo
RCMTSpecialty Health Care — Gross Profit
$13.44M+10.1%
Flexible Solutions International logo
FSIGross Profit
$1.89M-3.7%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GrossProfit.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Three Months Ended June 30, 2026Affordable Medicines (1)SpecialtyAv KARECorporateand OtherTotal Company
Net revenue$489,913$149,295$156,989$796,197
Cost of goods sold282,68448,265130,740461,689
Gross profit207,229101,03026,249334,508
Selling, general and administrative42,36740,09516,91349,347148,722
Research and development33,0235,99439,017
Intellectual property legal development expenses2,002852,087
Acquisition costs7,6007,600
Restructuring and other charges554554

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — gross profit?
Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — gross profit of $101.03M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — gross profit changed year-over-year?
Amneal Pharmaceuticals, Inc.'s specialty — gross profit increased by 39.8% year-over-year, from $72.25M to $101.03M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — gross profit?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — gross profit has grown at a 11.2% compound annual growth rate (CAGR), from $184.76M to $282.59M.
What does specialty — gross profit mean?
Calculated as net revenue minus the cost of goods sold for the specialty segment, representing the core profitability of the products before operating expenses. It serves as a key measure of the segment's pricing power and production cost management.

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — gross profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude